LifeVantage announces completion of international in vitro study on MB System

LifeVantage (LFVN) Corporation announced the completion of an international in vitro cell study that investigated the effects of its international formulation for the MindBody GLP-1 System, known as the MB System, on activating GLP-1 production. The international formula was designed to deliver all the benefits of the US formula while meeting regulatory requirements for all other markets in which LifeVantage operates. The study on the international formula, similar to the one completed on the US formula prior to its launch, was conducted on specialized L-cells found in the colon, where the body naturally produces GLP-1, a critical hormone in weight management and glucose regulation.